Clinical advances in front-line treatment of mantle cell lymphoma (MCL) over the past two decades have enhanced patient outcomes. However, even with the advances made in chemotherapy, chemo-immunotherapy and stem cell transplantation there is still no standardized front-line therapy for MCL and certain therapies can be used only in specific patient populations. Furthermore, with relapse of disease and resistance to current therapies being common in these patients, complex clinical challenges regarding disease management are prevalent. As our understanding of the biological events involved in the pathogenesis of MCL continues to develop and new therapeutic regimens and novel targeted agents are introduced into everyday clinical practice, healthcare professionals must be kept abreast of new strategies for the management of MCL and be able to evaluate the clinical implications of emerging data. Continued education, including expert guidance regarding disease pathogenesis and optimal integration of treatment regimens tailored to specific patient populations in both the front-line and relapsed/refractory setting will help enhance clinical outcomes and improvement patient quality of life.
In this presentation, Dr. Brad Kahl discusses the selection of front-line MCL therapies for optimizing outcomes in young vs. old patients.
Earn accreditation for this activity at the following location:
© 2014 Imedex, LLC.